20th Jan 2015 09:39
LONDON (Alliance News) - Oxford Pharmascience Group PLC Tuesday said it has successfully developed an immediate release clinical formulation of the OXPzero Naproxen non-steroidal anti-inflammatory drug and has accelerated the product to clinical proof-of-concept studies.
Oxford Pharmascience said it has hired Quotient Clinical as its clinical partner to run the proof-of-concept studies.
It expects headline results from the studies by the end of the first quarter, with headline endoscopy data expected in the second quarter.
"The progression to proof of concept studies for naproxen brings the company significantly closer to proving that the OXPzero proprietary platform technology can be applied across a range of molecules in the vast NSAIDs market, and to providing a robust data package to support the commercialisation of our NSAID clinical stage assets," said Marcelo Bravo, chief executive officer of Oxford Pharmascience.
Shares in Oxford Pharmascience were down 4.3% to 3.90 pence on Tuesday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Pharmascience Group